Company: CERO
Filing Date: 2025-04-22
Form Type: 8-K
Source: 0001213900-25-033946
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-22
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01. Other Events.

Private Placement Press Release

On April 22, 2025, the Company issued a press
release announcing the Private Placement.

A copy of the press release is filed as Exhibit
99.1 hereto and incorporated by reference herein.

Nasdaq Compliance

As previously disclosed, on January 17, 2025,
the Company received a letter setting forth the determination of a panel convened by Nasdaq (the “ Nasdaq Panel”) granting
the Company’s request for an extension (the “ Extension”) to regain compliance with certain continued listing
requirements of the Nasdaq Stock Market until April 22, 2025 (the “ Extension Date”). The Company presented its plan
(the “ Plan”) for regaining compliance with such requirements at a hearing conducted on December 17, 2025. The Company’s
Plan includes completion of a reverse stock split, which occurred on January 8, 2025, and transferring the listing of its securities to
the Nasdaq Capital Market, which was completed on February 12, 2025, and certain other conditions, including the satisfaction of the $2.5
million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.

In addition, as previously disclosed, from November
2024 through January 2025, the Company raised approximately $2.3 million of net proceeds from its equity line of credit entered into November
2024, and an additional approximately $4.1 million of net proceeds from its public offering of shares of common stock, pre-funded warrants
and warrants to purchase shares of common stock that closed on February 7, 2025 (the “February Offering”). As a result
of such capital raising activities and the proceeds of the Private Placement received on the First Closing Date, as well as successful
negotiations with certain service providers to reduce outstanding balances payable, the Company believes that it has stockholders’
equity of $2.5 million requirement as of the date of this filing and is awaiting a compliance determination from Nasdaq. Until Nasdaq
has reached a final determination that the Company has regained compliance with all of the applicable continued listing requirements,
there can be no assurances regarding the continued listing of the Company’s common stock and warrants on the Nasdaq Capital Market
and the Company could be subject to delisting.